Protein Summary
Component of the Nup107-160 subcomplex of the nuclear pore complex (NPC). The Nup107-160 subcomplex is required for the assembly of a functional NPC. The Nup107-160 subcomplex is also required for normal kinetochore microtubule attachment, mitotic progression and chromosome segregation. Bidirectional transport of macromolecules between the cytoplasm and nucleus occurs through nuclear pore complexes (NPCs) embedded in the nuclear envelope. NPCs are composed of subcomplexes, and NUP43 is part of one such subcomplex, Nup107-160 (Loiodice et al., 2004 [PubMed 15146057]).[supplied by OMIM, Mar 2008]
- ENST00000340413
- ENSP00000342262
- ENSG00000120253
- ENST00000367404
- ENSP00000356374
- p42
- bA350J20.1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
pathway | 1 | ||
transcription factor perturbation | 0.74 | ||
cellular component | 0.7 | ||
biological process | 0.67 | ||
transcription factor binding site profile | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 11.19 (req: < 5)
Gene RIFs: 2 (req: <= 3)
Antibodies: 195 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 11.19 (req: >= 5)
Gene RIFs: 2 (req: > 3)
Antibodies: 195 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0